Products for Research Use Only
RegisterLogin

Vactosertib

CAT: 0804-HY-19928-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-19928-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Vactosertib (EW-7197) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC50 of 12.9 nM. Vactosertib also inhibits ALK2 and ALK4 (IC50 of 17.3 nM) at nanomolar concentrations. Vactosertib has potently antimetastatic activity and anticancer effect[1][2].
CAS Number
1352608-82-2
Product Name Alternative
EW-7197; TEW-7197
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
TGF-β Receptor
Type
Reference compound
Related Pathways
TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/EW-7197.html
Purity
99.53
Solubility
DMSO : 100 mg/mL (ultrasonic) |Ethanol : 100 mg/mL (ultrasonic)
Smiles
CC1=CC=CC(C2=C(C3=CN4C(C=C3)=NC=N4)NC(CNC5=CC=CC=C5F)=N2)=N1
Molecular Formula
C22H18FN7
Molecular Weight
399.42
Precautions
H302, H315, H319, H335
References & Citations
[1]Son JY et al. EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis, 2014 Jul, 13 (7) :1704-16.|[2]Naka K, et al. Novel oral transforming growth factor-β signaling inhibitor EW-7197 eradicates CML-initiating cells. Cancer Sci. 2016 Feb;107 (2) :140-8.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
ALK5

Alternative Products

CatalogName
558278Vactosertib
CEC61025-01Vactosertib Hydrochloride
565040Vactosertib HCl
S7530-5mgVactosertib (TEW-7197)
A14213-1000EW-7197 (Vactosertib) 1g
A14213-500EW-7197 (Vactosertib) 500mg
A14213-100EW-7197 (Vactosertib) 100mg
A14213-50EW-7197 (Vactosertib) 50mg
A14213-2EW-7197 (Vactosertib) 2mg
A14213-25EW-7197 (Vactosertib) 25mg

Popular Products